Treatment with sorafenib in advanced thyroid cancer - A case report

Endokrynologia Polska

Volumn 61, Issue 5, 2010, Pages 492-496

  Krajewska, Jolanta ^a   Olczyk, Tomasz ^a   Roskosz, Józef ^a   Paliczk Cieślik, Ewa ^a   Kukulska, Aleksandra ^a   Śmietana, Anetta ^b   Kaczmarek Borowska, Bozenna ^b   Jarza̧b, Barbara ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b Subcarpathian Oncology Centre   (Poland)

Author keywords

Differentiated thyroid cancer; Radioiodine resistant; Sorafenib

Indexed keywords

DOXORUBICIN; IODINE 131; SORAFENIB; THALIDOMIDE;

ADULT; ADVANCED CANCER; ARTICLE; BONE METASTASIS; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CASE REPORT; CENTRAL NERVOUS SYSTEM METASTASIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG WITHDRAWAL; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MASTICATORY MUSCLE; RADIOISOTOPE THERAPY; SPINE METASTASIS; THYROGLOBULIN BLOOD LEVEL; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; BRAIN NEOPLASMS; DOXORUBICIN; FATAL OUTCOME; HUMANS; HYPOPARATHYROIDISM; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PYRIDINES; REOPERATION; THALIDOMIDE; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 78650030826     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Nucera C, Goldfarb M, Hodin R et al. Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E). Biochim Biophys Acta 2009; 1795: 152-161.
2. Woyach JA, Shah MH. New therapeutic advances in the management of progressive thyroid cancer. Endocr Relat Cancer 2009; 16: 715-731.
3. Deshpande HA, Gettinger SN, Sosa JA. Targeted therapy for thyroid cancer: An updated review of investigational agents. Curr Opin Investig Drugs 2010; 11: 661-668.
4. Fagin JA. How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. J Endocrinol 2004; 183: 249-256.
5. Lanzi C, Cassinelli G, Nicolini V et al. Targeting RET for thyroid cancer therapy. Biochem Pharmacol 2009; 77: 297-309.
6. Hundahl SA, Fleming ID, Fremgen AM et al. A National Cancer Data Base Report on 53,856 Cases of Thyroid Carcinoma Treated in the U.S. 1985-1995. Cancer 1998; 83: 2638-2648
7. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994; 97: 418-428. (Pubitemid 24345593)
8. Cooper DS, Doherty GM, Haugen BR et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Thyroid. 2009; 19: 1167-1214.
9. Durante C, Haddy N, Baudin E et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006; 91: 2892-2899.
10. Ain KB, Lee C, Williams KD. Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas. Thyroid 2007; 17: 663-670. (Pubitemid 47311556)
11. Ratain MJ, Eisen T, Stadler WM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 2505-2512.
12. Cabanillas ME, Waguespack SG, Bronstein Y et al. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. J Clin Endocrinol Metab 2010; 95: 2588-2595.
13. Carlomagno F, Anaganti S, Guida T et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 2006; 98: 326-334. (Pubitemid 43338212)
14. Gupta-Abramson V, Troxel AB, Nellore A et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008; 26: 4714-4719.
15. Kloos RT, Ringel MD, Knopp MV et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009; 27: 1675-1684.
16. Haugen BR, Kane MA. Approach to the thyroid cancer patient with extracervical metastases. J Clin Endocrinol Metab 2010; 95: 987-993.
17. Sherman SI. Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J Clin Endocrinol Metab 2009; 94: 1493-1499.
18. Hong DS, Sebti SM, Newman RA et al. Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clin Cancer Res 2009; 15: 7061-7068.
19. Kim S, Yazici YD, Calzada G et al. Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Mol Cancer Ther 2007; 6: 1785-1792. (Pubitemid 46954055)
20. Cakir M, Grossman AB. Medullary thyroid cancer: molecular biology and novel molecular therapies. Neuroendocrinology 2009; 90: 323-348.
21. Hong D, Ye L, Gagel R et al. Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib. Mol Cancer Ther 2008; 7: 1001-1006.
22. Lam ET, Ringel MD, Kloos RT et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 2010; 28: 2323-2330.
23. Sugawara M, Geffner DL, Martinez D et al. Novel treatment of medullary thyroid cancer. Curr Opin Endocrinol Diabetes Obes 2009; 16: 367-372.
24. Waguespack SG, Sherman SI, Williams MD et al. The successful use of sorafenib to treat pediatric papillary thyroid carcinoma. Thyroid 2009; 19: 407-412.